Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

Geoffrey L. Uy, MD, Jun Yin, PhD, Heidi D. Klepin, MD, Shira Dinner, MD, Anthony J. Jaslowski, MD, Stephen A. Strickland, MD, Jane L. Liesveld, MD, John C. Byrd, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 1366.

https://doi.org/10.1182/blood-2019-127142

Published: 2019

Journal Articles

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Matthew J. Wieduwilt, MD PhD, Jun Yin, PhD, Meir Wetzler, MD, Geoffrey L. Uy, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Michaela Liedtke, MD, Wendy Stock, MD, Jan H Beumer, Ryan J. Mattison, MD, Elizabeth Storrick, Steven Devine, Scott E. Smith, MD PhD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2018) 132 (Supplement 1): 309.

https://doi.org/10.1182/blood-2018-99-120029

Published: 2018

Journal Articles

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Jun Yin, PhD, Geoffrey L. Uy, MD, Betsy Laplant, MS, Elizabeth Storrick, Guido Marcucci, Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD

Blood (2018) 132 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2018-99-113902

Published: 2018

Journal Articles

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Matthew J. Wieduwilt, MD PhD, Jun Yin, PhD, Meir Wetzler, MD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Michaela Liedtke, MD, Wendy Stock, MD, Jan H. Beumer, PharmD, PhD, Ryan J. Mattison, MD, Alese Halvorson, Steven M. Devine, MD, Scott Smith, MD PhD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2016) 128 (22): 2782.

https://doi.org/10.1182/blood.V128.22.2782.2782

Published: 2016

Journal Articles

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Jun Yin, PhD, Betsy R. Laplant, MS, Geoffrey L. Uy, MD, Guido Marcucci, MD, William Blum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra Mandrekar, PhD

Blood (2016) 128 (22): 214.

https://doi.org/10.1182/blood.V128.22.214.214

Published: 2016

NARROW

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only